A growing number of addiction specialists are exploring a new application for the weight-loss medication Zepbound, originally developed to treat obesity. Patients, like Susan Akin, are reporting significant reductions in cravings for substances such as cocaine and alcohol after receiving weekly injections. Akin, who sought treatment at Caron Treatment Centres in Florida following a serious incident involving her car, has experienced a remarkable shift in her relationship with addictive substances since beginning the treatment.
While U.S. regulators have not officially approved GLP-1 medications like Zepbound for behavioral health issues, practitioners are increasingly prescribing them off-label. The initial anecdotal evidence suggests that these drugs may serve as valuable tools in addressing addiction, particularly in a landscape where traditional treatments are often limited or stigmatized.
Research and Potential of GLP-1 Medications
The mechanism by which GLP-1 drugs operate is not fully understood, but researchers hypothesize that they may influence brain chemistry by dampening dopamine release, which plays a key role in the brain’s reward system. Kyle Simmons, a professor at Oklahoma State University, notes that this could explain the drugs’ broader effects on behavior.
Clinical studies have begun to support the potential benefits of these medications for addiction treatment. For instance, a study published in February 2024 in JAMA Psychiatry indicated that problem drinkers receiving semaglutide injections reduced their alcohol consumption and cravings compared to those who were given a placebo. The National Institute on Drug Abuse is conducting ongoing research to better understand how GLP-1 drugs could help individuals with alcohol use disorders.
Research into the efficacy of GLP-1 medications is expanding to various demographics, including veterans with substance use issues and patients with diabetes who smoke. Despite the promising preliminary findings, these medications remain expensive, and health insurance often does not cover them for addiction treatment.
Personal Stories and Financial Challenges
For patients like Akin, the weekly injections have made daily life more manageable. She describes the impact of Zepbound on her cravings, stating, “I know when I’m due for my shot because I get a little antsy or irritable, or just kind of off. But it has changed my life.”
Despite its benefits, the financial burden of GLP-1 medications can be significant. Akin spends nearly $1,000 each month on her prescribed shots, relying on her inheritance to afford the treatment. As pharmaceutical companies like Eli Lilly and Novo Nordisk consider lowering prices, many patients remain uncertain about their ability to sustain such costs without insurance coverage.
Steven Klein, an addiction specialist at Caron and a recovering alcoholic himself, began prescribing GLP-1s to his patients after experiencing their effects firsthand during his own recovery journey. He has initiated a pilot program that has already treated over 130 patients with alcohol use disorders. Klein emphasizes the potential of these medications to assist individuals struggling with addiction, highlighting that “it helps. It slows things down enough to the point where you don’t feel like you have to jump off a bridge or put your head in a cocaine plant to survive.”
As research continues, addiction treatment facilities are beginning to integrate GLP-1 medications into their recovery programs. Klein has partnered with Open Doors, a nonprofit organization that aids formerly incarcerated women in their re-entry into society. This collaboration aims to provide GLP-1 treatments to those who often face significant challenges in maintaining sobriety after rehabilitation.
Regina Roberts, a resident at Open Doors, has found hope in these treatments. Since beginning GLP-1 therapy, she has experienced fewer cravings, which allows her to focus on rebuilding her life and reconnecting with her teenage son. However, like Akin, Roberts faces the uncertainty of whether she can afford ongoing treatment without insurance support.
The potential of GLP-1 medications to reshape addiction treatment strategies presents an exciting avenue for research and clinical practice. With an estimated 48 million Americans facing substance use disorders in 2024 and over 80,000 dying from drug overdoses, the need for effective treatments is more pressing than ever. If GLP-1s can prove effective in reducing cravings for various substances, addiction specialists believe they could represent a significant advancement in therapeutic options for individuals struggling to regain control of their lives.
